IMR Press / EJGO / Volume 31 / Issue 3 / pii/1630985096416-650292652

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Case Report
Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer
Show Less
1 Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center
2 Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei (Taiwan)
Eur. J. Gynaecol. Oncol. 2010, 31(3), 350–353;
Published: 10 June 2010
Abstract

Management of patients with recurrent or advanced cervical cancer is a challenge. Concurrent chemotherapy has become the mainstay of treatment and platinum remains the most effective single agent. Combinations of other agents have not demonstrated significant advantages. The application of angiogenesis inhibitors such as bevacizumab, an antibody inhibiting vascular endothelial growth factor, in metastatic or advanced cervical cancer remains to be evaluated. We present the case of a patient with platinumresistant recurrent cervical cancer treated with low-dose bevacizumab and carboplatin, with resultant improved disease progression and tolerable toxicity profiles.
Keywords
Bevacizumab
Cervical cancer
Metronomic
Share
Back to top